Become Part Of Clearsights’ Network
A strategic partnership model that supports clinical independence, operational excellence and shared success.
Corneal cross-linking is a minimally invasive treatment that uses a combination of riboflavin (vitamin B2) eye drops and controlled ultraviolet (UV) light to strengthen the corneal tissue.
It is most commonly used to treat:
The treatment works by increasing the natural bonds within the cornea, making it more stable and resistant to further deformation.
Conditions such as keratoconus cause the cornea to progressively thin and change shape, leading to distorted vision.
Cross-linking is recommended to:
While it does not reverse existing changes, it plays a critical role in stabilising the condition early.
Not all patients require immediate treatment.
Careful monitoring is essential to determine whether the condition is progressing and when intervention is most beneficial.
Your specialist will assess:
Treatment is recommended when there is clear evidence of progression.
Corneal cross-linking is typically performed as a day procedure under local anaesthetic.
There are two main approaches:
During the procedure:
Recovery varies depending on the technique used.
Following treatment:
Most patients return to normal activities within a few days to a week, with vision continuing to stabilise over time.
Corneal cross-linking is highly effective at stabilising keratoconus and related conditions.
Most patients experience:
Early treatment is key to achieving the best long-term outcomes.
Corneal cross-linking is a proactive treatment — designed to preserve rather than restore.
With timely intervention and specialist care, it offers a reliable way to protect your vision and maintain long-term eye health.